Napo Pharmaceuticals Launches Mytesi (crofelemer) as the Only FDA-Approved Treatment for Relief of Noninfectious Diarrhea in HIV+ Patients
Launch Includes Copay Savings and Patient Assistance Programs to Ensure Affordable Access to Mytesi™, Formerly Marketed as Fulyzaq®